Clinical Trial Update: Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial investigating enzalutamide as neoadjuvant therapy before prostatectomy in localized prostate cancer completed with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Enzalutamide (enzalutamide)

Snippet

Sponsor: Pfizer | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2015-04-10